The Journal Of Dermatological Treatment[JOURNAL]
Sun
200 papers
Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.
Wollenberg A, Costanzo A, Vestergaard C … +6 more , Masuda K, Morawska K, Vardar B, Pandey H, Sabatino S, Carrascosa JM
J Dermatolog Treat · 2025 Dec · PMID 41306112 · Publisher ↗
OBJECTIVE: To report response maintenance in patients with moderate-to-severe Atopic Dermatitis (AD) upon continuous or downtitrated baricitinib treatment for 200 weeks. METHODS: Patients with vIGA-AD (validated Investig...
OBJECTIVE: To report response maintenance in patients with moderate-to-severe Atopic Dermatitis (AD) upon continuous or downtitrated baricitinib treatment for 200 weeks. METHODS: Patients with vIGA-AD (validated Investigator Global Assessment for Atopic Dermatitis) score ≤2 at Week 52 treated with baricitinib 4 mg were re-randomized (1:1:1) to continue (4 mg), down-titrate (2 mg) or dose withdrawal (placebo). Response to continuous and downtitrated treatment was assessed from Week 52 to 200 in the overall substudy population (vIGA-AD 0,1,2) and in substudy patients with higher response (vIGA-AD 0,1) at Week 52. RESULTS: Efficacy was maintained in Week 52 responders (vIGA-AD 0,1,2) continuing baricitinib 4 mg, as measured by vIGA-AD (0,1) (Week 52 [51.2%], Week 200 [51.2%]); Eczema Area and Severity Index (EASI) 75 (Week 52 [82.1%], Week 200 [79.8%]). Patients with vIGA-AD (0,1) at Week 52 maintained higher response rates during continued treatment and after down-titration compared with overall substudy population. CONCLUSION: AD symptom improvement was maintained up to Week 200 with baricitinib 4 mg. After down-titration, the vIGA-AD (0,1) response patient subgroup maintained clear or almost clear skin and itch response improvement. Clear or almost clear skin achievement may help identify optimal candidates for down-titration after 52 weeks of full-dose treatment.
Reconsidering quantification and mechanistic inference in platelet-rich plasma research for androgenetic alopecia.
Tringali S
J Dermatolog Treat · 2025 Dec · PMID 41292072 · Publisher ↗
Abstract loading — click title to view on PubMed.
Neoadjuvant plus adjuvant dabrafenib and trametinib versus adjuvant dabrafenib and trametinib in patients with stage III melanoma: a single-center retrospective cohort study.
Jia DD, Li T
J Dermatolog Treat · 2025 Dec · PMID 41290590 · Publisher ↗
OBJECTIVE: To assess the impact of combined neoadjuvant and adjuvant dabrafenib plus trametinib versus adjuvant-only therapy on event-free survival (EFS) in patients with resected stage III BRAF-mutant melanoma. METHODS:...
OBJECTIVE: To assess the impact of combined neoadjuvant and adjuvant dabrafenib plus trametinib versus adjuvant-only therapy on event-free survival (EFS) in patients with resected stage III BRAF-mutant melanoma. METHODS: Data from patients with confirmed stage III BRAFV600E/K-mutant melanoma treated at Zhejiang Cancer Hospital between May 2019 and December 2023 were retrospectively analyzed. A total of 32 patients were included (neoadjuvant + adjuvant, = 10; adjuvant-only, = 22). RESULTS: There was no statistically significant difference in EFS between the groups (log-rank = 0.55), nor were there significant differences in OS observed (log-rank = 0.82). Surgical resection was performed on all patients in the combined therapy group, with 50% achieving a pathological complete response (pCR) and the remaining 50% a pathological partial response (pPR). No significant differences in EFS (log-rank = 0.09) or OS (log-rank = 0.11) were found based on the pathological response. The toxicity profile was consistent with previous reports. CONCLUSION: In this single-center retrospective cohort, neoadjuvant-plus-adjuvant dabrafenib and trametinib was feasible, enabling timely surgery with manageable toxicities. Survival outcomes were comparable to adjuvant-only therapy, and pathological responses in the neoadjuvant cohort provide exploratory prognostic information.
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.
Diao Q, Jia R, Li M … +8 more , Zhao P, Lu F, Zhang Q, Ning C, Long J, Li J, Huang Y, Wang Y
J Dermatolog Treat · 2025 Dec · PMID 41288059 · Publisher ↗
BACKGROUND: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). OBJECTIVE: This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in m...
BACKGROUND: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). OBJECTIVE: This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments. METHODS: This was a post-hoc analysis of a phase III clinical trial of Ivarmacitinib in moderate-to-severe AD (NCT04875169). Subgroup analysis by with ( = 132) or without ( = 204) previous systemic treatments (systemic corticosteroids, biologics, or other immunomodulators) was performed. RESULTS: In patients with previous systemic treatments, Ivarmacitinib 8 mg ( = 34) and 4 mg ( = 53) exhibited higher Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI)-75, EASI-90, and Worst Itch Numeric Rating Scale (WI-NRS) 4 response rates, and a greater reduction in Dermatology Life Quality Index (DLQI) score compared with placebo ( = 45) at most timepoints from W4 to W16. In patients without previous systemic treatments, these outcomes were notably increased in Ivarmacitinib 8 mg ( = 78) and 4 mg ( = 60) versus placebo ( = 66) throughout W4 to W16. The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments. CONCLUSION: Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.
Kimura disease responded well to tofacitinib in three cases.
Cao M, Xiao Y, Wang Y
J Dermatolog Treat · 2025 Dec · PMID 41277429 · Publisher ↗
AIM: Kimura disease (KD) is a rare inflammatory disorder with an unclear etiology. Although multiple treatment options are available, managing KD remains challenging due to variable treatment effectiveness, high recurren...
AIM: Kimura disease (KD) is a rare inflammatory disorder with an unclear etiology. Although multiple treatment options are available, managing KD remains challenging due to variable treatment effectiveness, high recurrence rates, and potential adverse effects. Thus, there is an urgent need for novel, effective, and well-tolerated therapeutic strategies for KD patients. METHODS: Here we report three KD cases treated with tofacitinib, a Janus kinase (JAK) inhibitor, at a dosage of 5 mg twice daily. RESULTS: Significant softening and reduction in lesion size were observed in all three patients within 2 months, with complete lesion resolution after 6-20 months of treatment. The therapy was well-tolerated, and no relapses occurred during 5-9 months of follow-up after discontinuing tofacitinib. CONCLUSIONS: Our report provides valuable clinical evidence that tofacitinib is a promising novel therapeutic option for KD, demonstrating its safety and durable efficacy.
Cross-spectrum efficacy of spesolimab in IL-36-mediated dermatoses: a 'case study.
Tong R, Chen C, Huang L … +1 more , Ni C
J Dermatolog Treat · 2025 Dec · PMID 41277373 · Publisher ↗
The nosological distinction between acute generalized exanthematous pustulosis (AGEP) and generalized pustular psoriasis (GPP) has become increasingly unclear due to shared IL-36 pathway dysregulation. This case highligh...
The nosological distinction between acute generalized exanthematous pustulosis (AGEP) and generalized pustular psoriasis (GPP) has become increasingly unclear due to shared IL-36 pathway dysregulation. This case highlights an important clinical gap: the therapeutic response to IL-36 inhibition in AGEP with wild-type IL36RN. A 15-year-old female with ERASPEN-confirmed GPP developed hydroxychloroquine-induced AGEP (EuroSCAR score = 7) despite wild-type IL36RN and CARD14. Ten days after hydroxychloroquine exposure, she presented with widespread erythema, pustules, targetoid lesions, and fever (39 °C). Histopathology revealed subcorneal pustules with eosinophilic infiltration. Acitretin provided no benefit, and cyclosporine (150 mg/day) produced only transient improvement before relapse. A single intravenous dose of spesolimab (450 mg) led to complete pustular clearance within 18 days. Sustained remission (GPPGA = 0) was observed at 5-month follow-up. Spesolimab produced rapid and durable control of IL-36-driven AGEP independent of IL36RN mutation status. These findings support IL-36 receptor blockade as a targeted therapeutic option for refractory AGEP and further position AGEP and GPP along a shared IL-36-mediated disease spectrum.
Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study.
Muñoz-Barba D, García-Moronta C, Haselgruber-de Francisco S … +2 more , Sánchez-Díaz M, Arias-Santiago S
J Dermatolog Treat · 2025 Dec · PMID 41277365 · Publisher ↗
BACKGROUND AND OBJECTIVES: Baricitinib was effective in treating severe alopecia areata (AA) in clinical trials, yet real-world prospective data remain scarce. The aim of this study was to assess real-world effectiveness...
BACKGROUND AND OBJECTIVES: Baricitinib was effective in treating severe alopecia areata (AA) in clinical trials, yet real-world prospective data remain scarce. The aim of this study was to assess real-world effectiveness and safety of Baricitinib. PATIENTS AND METHODS: A prospective observational study was conducted including 48 adults with severe AA over a 12-month follow-up. Clinical response, laboratory data, and adverse events were assessed. Predictors of response were also explored. The primary endpoint was defined as the attainment of a Severity of Alopecia Tool (SALT) score <20%, sustained over at least two consecutive assessments separated by ≥12 weeks within the first year of therapy. RESULTS: A clinically meaningful response (SALT <20) was achieved by 58.3% of patients and 37.5% achieved a complete response (SALT <10). Early responders represented 29.5% of the cohort. Eyebrow and eyelash regrowth improved ( < 0.01). Predictors of favorable response included lower baseline SALT, shorter disease duration, and higher basal erythrocyte sedimentation rate (ESR). No serious adverse events were reported. CONCLUSIONS: Baricitinib is effective and safe in the real-world management of severe AA, especially when initiated early in patients with lower baseline severity and elevated ESR. These findings highlight the relevance of timely intervention and appropriate patient selection.
Discrete choice experiment in treatment preferences for atopic dermatitis: a systematic review.
Wang Y, Liu S, Du Y … +4 more , Wang L, Rong W, Shi Y, Liu C
J Dermatolog Treat · 2025 Dec · PMID 41263013 · Publisher ↗
OBJECTIVES: This study systematically reviews relevant studies on the application of discrete choice experiment (DCE) in treatment preference selection for atopic dermatitis (AD), with the aim of providing reference for...
OBJECTIVES: This study systematically reviews relevant studies on the application of discrete choice experiment (DCE) in treatment preference selection for atopic dermatitis (AD), with the aim of providing reference for the future application of DCE in clinical practice. METHODS: Relevant studies were retrieved from PubMed, Web of Science, Embase, Cochrane Library, CINAHL, Medline, WanFang Data and CNKI databases. The search time restricted to the establishment of the database to 22 October 2025. Two researchers independently conducted literature screening, after which they extracted data, and carried out quality evaluation using the PREFS scoring criteria. RESULTS: A total of 13 studies were included, mainly from European and American countries. According to the PREFS scale, 8 studies were rated 4 points and 5 studies 3 points in quality assessment. The main data analysis model was random parameter Logit. CONCLUSIONS: The research on the application of DCE in assessing AD treatment preferences is still in the development stage, with room for further improvement regarding respondents. Future relevant studies should adhere to the experimental design principles of DCE, while attaching importance to result attributes, so as to provide more high-quality evidence for research on AD treatment preferences.
Safety of secukinumab in pregnant patients with pustular psoriasis: a case report on two successful pregnancies and their offspring outcomes.
He M, Zhang M, Jia M … +3 more , Yu T, Sun L, Tang T
J Dermatolog Treat · 2025 Dec · PMID 41261900 · Publisher ↗
OBJECTIVE: Generalized pustular psoriasis of pregnancy (GPPP) is a rare and serious skin disease. Although IL-17A inhibitors have shown potential for safety and efficacy during pregnancy, further evidence is needed. This...
OBJECTIVE: Generalized pustular psoriasis of pregnancy (GPPP) is a rare and serious skin disease. Although IL-17A inhibitors have shown potential for safety and efficacy during pregnancy, further evidence is needed. This study aimed to evaluate the efficacy and safety of secukinumab administered during two consecutive pregnancies, with an emphasis on long-term follow-up of the offspring. MATERIALS AND METHODS: This case report described a 21-year-old female patient who received secukinumab treatment for GPPP during two consecutive pregnancies. Clinical efficacy was assessed using the Generalized Pustular Psoriasis Area and Severity Index (GPPASI), the Generalized Pustular Psoriasis Global Assessment (GPPGA), and the Dermatology Life Quality Index (DLQI). Regular follow-up evaluations were conducted to monitor potential manifestations of psoriasis in the offspring and assess their vaccination status. RESULTS: After first - pregnancy secukiumab injection, GPPASI, GPPGA, and DLQI scores dropped rapidly; similar efficacy occurred in the second pregnancy with no adverse events. Vaccination confers no immunosuppression or infection risk in offspring. CONCLUSIONS: Secukinumab showed a favorable safety profile for both mother and infant in two consecutive pregnancies. Importantly, no immune abnormalities were noted in the offspring after receiving attenuated live vaccines, indicating that secukinumab may not affect vaccine efficacy.
An open single-arm clinical study of microneedle radiofrequency technology for addressing abdominal skin laxity in postpartum women.
Bai Y, Zhang Y, Bai Y … +3 more , Li J, Fu X, Yao M
J Dermatolog Treat · 2025 Dec · PMID 41255263 · Publisher ↗
OBJECTIVES: Postpartum abdominal skin laxity represents a common yet challenging condition, with increasing demand for effective and safe noninvasive or minimally invasive treatments, such as phototherapy, radiofrequency...
OBJECTIVES: Postpartum abdominal skin laxity represents a common yet challenging condition, with increasing demand for effective and safe noninvasive or minimally invasive treatments, such as phototherapy, radiofrequency (RF), and ultrasound, due to their controlled penetration depth and lower risks. Conventional treatments are limited by reason of thermal injury risk and long recovery periods, necessitating safer and more effective interventions. METHODS: This open-label, single-arm study evaluated bipolar microneedle radiofrequency (MNRF) for treating abdominal skin laxity in 17 postpartum women. Participants received three treatments at 8-week intervals. Assessments included global aesthetic improvement, abdominal circumference (AC), biomechanical properties, and patient satisfaction. RESULTS: Significant improvements were observed in skin elasticity, viscoelasticity, and echo density; AC showed a non-significant reduction trend with notable aesthetic enhancement. Histological analysis in one subject showed increased collagen density and restoration of the dermal-epidermal junction. Eighty percent of the subjects expressed satisfaction during the treatment period, with a subjective comfort score of 2.93 ± 1.29 (0-10) and an overall satisfaction of 2.40 ± 0.88 (0-4), and no serious adverse events occurred. CONCLUSIONS: These results indicate that bipolar MNRF is an effective and safe minimally invasive option for improving postpartum abdominal laxity.
Temporal trends and real-world effectiveness of biologic therapies in generalized pustular psoriasis: a 7-year retrospective cohort study.
Peng B, Cao Z, Fan R … +13 more , Li R, Li Z, Mi B, Song X, Niu H, Tao Y, Li B, Jing S, Kong S, Zhu Y, Hu W, Li F, Geng S
J Dermatolog Treat · 2025 Dec · PMID 41251273 · Publisher ↗
INTRODUCTION: Generalized pustular psoriasis (GPP) is a severe, life-threatening disease with a particularly high burden in Asian populations. However, real-world evidence on the effectiveness of biologic therapies remai...
INTRODUCTION: Generalized pustular psoriasis (GPP) is a severe, life-threatening disease with a particularly high burden in Asian populations. However, real-world evidence on the effectiveness of biologic therapies remains limited, especially in resource-limited settings. OBJECTIVES: To describe the clinical profiles, treatment patterns and outcomes, and assess the impact of therapies on disease recurrence in GPP inpatients. METHODS: This retrospective cohort study analyzed hospitalized patients with GPP treated at a tertiary referral center in China between March 2017 and February 2024. Patients were reassessed according to Asia-Pacific consensus criteria. RESULTS: A total of 322 inpatients with moderate-severe GPP were included, recording 419 hospitalizations. There were 212 GPP with psoriasis vulgaris (GPP+PV) and 110 GPP-PV patients, showing differences in clinical characteristics, including comorbidities. Over the 7-year study period, biologic utilization increased from 0 to 57.0%, while total annual hospitalizations decreased by 38.9%. Patients receiving biologics monotherapy demonstrated significantly better outcomes than those receiving traditional therapies, including shorter mean hospitalization duration (6.1 ± 3.4 vs. 9.2 ± 3.3 days, < 0.001), faster pustule clearance (4.2 ± 2.6 vs. 6.8 ± 3.0 days, = 0.001), and significantly lower recurrence rates. Multivariate analysis demonstrated, for the first time, the independent treatment effect of biologic-targeted therapy. Survival analysis confirmed significantly shorter median time to achieve GPPGA 0/1 (6 vs. 9 days, log-rank < 0.001) and complete pustule clearance (5 vs. 11 days, log-rank < 0.001) with biologics. Among all follow-up patients, the recurrence rate dropped from 51.7% to 29.3%, with only biologics significantly reducing flare frequency at post-discharge compared with pre-discharge (0.6 ± 0.3 vs. 1.4 ± 0.9 flares/person-year, = 0.016). CONCLUSION: These findings provide robust real-world evidence that biologics significantly improve both acute and long-term outcomes in GPP, supporting their use as first-line therapy and underscoring the need to improve global access to these treatments.
When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review.
Shanshal M
J Dermatolog Treat · 2025 Dec · PMID 41243342 · Publisher ↗
BACKGROUND: Janus kinase (JAK) inhibitors have revolutionized alopecia areata (AA) treatment, but many patients remain ineligible or lack access. Corticosteroid pulse regimens provide valuable systemic alternatives in th...
BACKGROUND: Janus kinase (JAK) inhibitors have revolutionized alopecia areata (AA) treatment, but many patients remain ineligible or lack access. Corticosteroid pulse regimens provide valuable systemic alternatives in these scenarios. CASE PRESENTATION: A 52-year-old woman with systemic lupus erythematosus and renal transplant presented with extensive AA (SALT score 90). Due to intensive immunosuppression, JAK inhibitors were deemed clinically unsuitable. She received dexamethasone oral mini-pulse (OMP) therapy: 5 mg on two consecutive days weekly for four months. At six-month follow-up, her SALT score improved dramatically to 21, achieving SALT75 response and approaching the clinically significant SALT ≤ 20 threshold. This regrowth sustained at 12 months without maintenance therapy or steroid-related adverse events. EVIDENCE SYNTHESIS: Review of 14 clinical studies revealed OMP's high efficacy, with 89% patient improvement and 71% median SALT reduction by week 24. Randomized trials show oral steroid pulse therapy can outperform placebo (weekly prednisolone), and betamethasone OMP outperformed methotrexate in an active-comparator trial. However, relapse occurs in approximately 60% of responders post-withdrawal. Intravenous methylprednisolone pulses showed 73% response rates at 12 months, particularly in early multifocal disease. CONCLUSIONS: In JAKi-ineligible settings, OMP provides outpatient induction with acceptable safety. This case demonstrates achievable 12-month durable remission even in complex, high-risk, immunosuppressed patients.
Clinical characteristics, treatment outcomes and prognostic factors of ulcerated infantile hemangioma: 15 years of experience from a pediatric dermatology center in Hong Kong.
Chu AKY, Cheng JWC, Lam YY … +2 more , Bao WKJ, Luk DCK
J Dermatolog Treat · 2025 Dec · PMID 41221590 · Publisher ↗
OBJECTIVES: To evaluate the clinical characteristics and therapeutic outcomes of ulcerated infantile hemangioma (IH) and identify prognostic factors of ulcerated IH. METHODS: A single-center retrospective study recruitin...
OBJECTIVES: To evaluate the clinical characteristics and therapeutic outcomes of ulcerated infantile hemangioma (IH) and identify prognostic factors of ulcerated IH. METHODS: A single-center retrospective study recruiting patients with ulcerated IH between 2008 and 2023 was conducted. Clinical features and treatment response were analyzed to identify prognostic factors of ulcerated IH and differences in outcomes between early versus late pediatric dermatology referral. RESULTS: A total of 85 patients with ulcerated IH were included. Hemangiomas in the head and neck (H&N) and anogenital regions had an earlier presentation and occurrence of ulceration. Large hemangiomas or ulcers, combined/mixed IH, lip hemangiomas, and positive microbial growth were significant prognostic indicators for longer healing time, more complications and recurrence of ulceration. Cheek hemangiomas, focal IH and later onset ulceration were associated with less scarring and complications. Early referrals before ulceration had less ulcer recurrence (odds ratio [OR] = 0.139; 95% confidence interval [CI]: 0.028-0.693] and secondary complications (OR = 0.081 [95% CI: 0.019-0.348]). Prophylactic topical timolol maleate 0.5% was effective in reducing scar formation (OR = 0.06 [95% CI: 0.005-0.75]) and shortening follow-up duration ( = 0.044). Combination therapy with oral propranolol and pulsed dye laser was the mainstay of treatment (74%). Maintenance laser after ulcer resolution was associated with less ulcer recurrence (OR = 0.27 [95% CI: 0.075-0.96]). CONCLUSION: Early referral of high-risk cases to a pediatric dermatology center before ulceration is crucial. Prophylactic topical timolol before ulceration and maintenance laser therapy after ulcer resolution can improve outcomes.
A novel facial moisturizer containing Saccharide isomerate accelerates skin barrier restoration following intense pulsed light treatment: a randomized split-face study.
Shao H, Wang L, Wang Y … +10 more , Wang C, Chen L, Tang J, Zhang S, Chen Q, Dong R, Liao X, Hou Y, Yang J, Li W
J Dermatolog Treat · 2025 Dec · PMID 41211697 · Publisher ↗
BACKGROUND: Intense pulsed light (IPL) therapy is widely used for skin rejuvenation, but often impairs the skin barrier, causing discomfort and prolonging recovery. OBJECTIVES: To evaluate the efficacy and safety of a no...
BACKGROUND: Intense pulsed light (IPL) therapy is widely used for skin rejuvenation, but often impairs the skin barrier, causing discomfort and prolonging recovery. OBJECTIVES: To evaluate the efficacy and safety of a novel moisturizer containing saccharide isomerate in restoring skin barrier function and alleviating symptoms after IPL treatment in Chinese population. METHODS: In this split-face study, thirty subjects with skin aging received a single IPL treatment. Each participant applied the test moisturizer containing saccharide isomerate to one randomly assigned cheek and the control moisturizer to the contralateral side twice daily for 7 days. Key barrier function parameters were measured at baseline and repeatedly during study period. Adverse events were assessed at each of these follow-up time points. Additionally, overall subject satisfaction was evaluated at the end of the study. RESULTS: The test side showed significantly greater improvement in all biometric parameters (all < 0.05) and was associated with significantly less subjective discomfort. Both formulations were well-tolerated with no related adverse events. CONCLUSION: The saccharide isomerate-based moisturizer significantly accelerates skin barrier recovery, improves hydration, reduces erythema, alleviates discomfort and has a good safety profile with high subject satisfaction, making it a promising new option in the field of post-photoelectric surgery care.
Silicone-based fluid gel versus white paraffin ointment in the treatment of post-fractional ablative CO laser wound: an intra-individual split-face comparative study.
Alajlan A, AlHarbi S, Nagshabandi KN … +4 more , Alajlan A, AlHarbi B, AlMuqarrab FJ, Alsuwaidan S
J Dermatolog Treat · 2025 Dec · PMID 41195573 · Publisher ↗
BACKGROUND: Optimizing acute wound care after resurfacing lasers is essential for healing, downtime, and cosmetic outcomes. Demand for effective topicals has led to use of various products. OBJECTIVE: This study compares...
BACKGROUND: Optimizing acute wound care after resurfacing lasers is essential for healing, downtime, and cosmetic outcomes. Demand for effective topicals has led to use of various products. OBJECTIVE: This study compares the efficacy of silicone-based fluid gel versus white paraffin ointment in managing acute post-resurfacing laser wounds. METHODS: In this intra-individual, split-face study, 15 patients treated for acne scars applied silicone gel to one facial half and white paraffin to the other. Two blinded dermatologists assessed acute reactions using the VISIA Complexion Analysis system. Patient satisfaction was measured with two tools. RESULTS: The silicone-treated side showed greater erythema, pruritus, scaling, and crusting than the paraffin side, though differences were not statistically significant. VISIA demonstrated significantly worse redness, higher porphyrin levels, and greater textural change on the silicone side ( = 0.04), suggesting increased susceptibility to acneiform eruptions. Patient-reported outcomes and physician global assessments revealed no significant difference in overall aesthetic results between sides. CONCLUSION: White paraffin ointment provided comparable or superior management of acute post-resurfacing wounds. Silicone-based gel may elevate porphyrins and potentially predispose to acneiform eruptions, warranting further study.
Real-world outcomes of dupilumab therapy in moderate-to-severe atopic dermatitis patients: an observational retrospective study in Gulf countries.
Binamer Y, AlFalasi A, Alajlan M … +13 more , Abdulwahhab WS, BinSayyar F, Wani Z, Bichu S, Gadalla D, Alnasser MA, Elmorshidy G, Barakat A, Chmayse S, Hafiz M, Chouikrat Z, Jabaji D, Fahmy M
J Dermatolog Treat · 2025 Dec · PMID 41194686 · Publisher ↗
OBJECTIVES: Dupilumab has demonstrated strong efficacy and safety in clinical trials for atopic dermatitis (AD), but real-world data from the Greater Gulf region remain limited. This study aimed to evaluate the real-worl...
OBJECTIVES: Dupilumab has demonstrated strong efficacy and safety in clinical trials for atopic dermatitis (AD), but real-world data from the Greater Gulf region remain limited. This study aimed to evaluate the real-world effectiveness and safety of dupilumab in adolescents and adults with moderate-to-severe AD in Saudi Arabia and the United Arab Emirates. METHODS: A retrospective observational study was conducted in adolescents and adults (≥12 years) with moderate-to-severe AD, who had received dupilumab for one to three years. Clinical outcomes were assessed using SCORing Atopic Dermatitis (SCORAD) and the Dermatology Life Quality Index (DLQI), while safety was evaluated through reported adverse events (AEs). RESULTS: Ninety-five patients were eligible, with a mean age of 29.3 years, and 52.6% were males. The mean baseline SCORAD score was 49.9, which decreased markedly to 21.5 after one month, 12.7 after three months, and 14.1 at six months. At six months, data were available for 71 patients, of whom 76% achieved SCORAD-50 and 52.1% achieved SCORAD-75. Reported AEs were generally mild, the most frequent being dry eyes (14.7%), dry eyes with pruritus (8.4%), and facial erythema (6.3%). No serious AEs or treatment discontinuations were recorded. CONCLUSION: Dupilumab demonstrated sustained clinical improvements and favorable safety. These findings reinforce the results of previous real-world studies and Randomized Controlled Trials.
Comparative efficacy of omalizumab, dupilumab, and remibrutinib in chronic spontaneous urticaria: a network meta-analysis of randomized control trials.
Xiong G, Rayner DG, Kim L … +3 more , Mahmood S, Yu T, Abu-Hilal M
J Dermatolog Treat · 2025 Dec · PMID 41186128 · Publisher ↗
INTRODUCTION: Chronic spontaneous urticaria (CSU) is a skin condition that significantly impairs quality of life. While omalizumab remains the standard treatment for patients who have failed antihistamines, emerging ther...
INTRODUCTION: Chronic spontaneous urticaria (CSU) is a skin condition that significantly impairs quality of life. While omalizumab remains the standard treatment for patients who have failed antihistamines, emerging therapies show promise in randomized control trials (RCTs). This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU. METHODS: Four databases were searched for RCTs evaluating omalizumab (75/150/300 mg Q4W), dupilumab (300 mg Q2W), or remibrutinib (25 mg BID) in CSU. Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24. Frequentist random-effects network meta-analysis were conducted in R. RESULTS: Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks. CONCLUSION: Omalizumab 300 mg, followed by remibrutinib, exhibited the highest effect sizes across major outcomes for CSU. Newer therapies such as remibrutinib and dupilumab appear generally effective, offering promising tools for CSU patients who may not respond to standard treatments.
Clinical characteristics, treatment outcomes, and relapse prediction in 199 patients with generalized pustular psoriasis: a retrospective cohort study.
Li Z, Wu X, Wang Z … +9 more , Ge H, Liu Y, Zhu L, Zhang Z, Yang B, Yang Q, Liu G, Liu H, Zhang F
J Dermatolog Treat · 2025 Dec · PMID 41181907 · Publisher ↗
INTRODUCTION: Generalized pustular psoriasis (GPP) is a rare, life-threatening inflammatory disease with recurrent flares and clinical heterogeneity. Long-term management remains challenging due to limited evidence on tr...
INTRODUCTION: Generalized pustular psoriasis (GPP) is a rare, life-threatening inflammatory disease with recurrent flares and clinical heterogeneity. Long-term management remains challenging due to limited evidence on treatment efficacy and prognosis. OBJECTIVES: This study sought to optimize clinical management of GPP by evaluating treatment efficacy, prognostic factors including genetics, and developing a practical tool for relapse prediction. METHODS: This study involved 199 GPP patients, analyzing clinical, genetic, and treatment data. Treatment efficacy was evaluated using the Cox proportional hazards model. Multivariate logistic regression identified relapse predictors, incorporated into a nomogram and online tool. Model performance was evaluated using the area under the curve, calibration curves and decision curve analysis. RESULTS: IL36RN mutations were linked to earlier onset and increased systemic involvement. Biologic therapies, especially IL-36 inhibitors, showed better results than conventional treatments, with shorter hospital stays and faster pustule clearance. Biologics reduced relapse risk by 95%. Relapse predictors included a history of plaque psoriasis, elevated direct bilirubin (DBIL > 8 µmol/L), and biologic use. The relapse prediction model had good discrimination (AUC = 0.75) and stratified patients into high-, intermediate-, and low-risk groups (high-risk vs. low-risk: 9.51-fold higher recurrence). CONCLUSION: Biologics, particularly IL-36 inhibitors, improve GPP outcomes. DBIL is a novel biomarker for relapse risk. The validated online tool provides a practical way to personalize relapse prevention and treatment in clinical practice.
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors.
Gori N, Di Nardo L, Ippoliti E … +18 more , Antonelli F, Boeti L, Balato A, Di Brizzi EV, Nicoletti M, Esposito M, Fargnoli MC, De Berardinis A, Magnanimi LM, Galluzzo M, Paganini C, Talamonti M, Bianchi L, Napolitano M, Patruno C, Lauletta G, di Vico F, Peris K
J Dermatolog Treat · 2025 Dec · PMID 41181864 · Publisher ↗
OBJECTIVES: Baricitinib has shown efficacy and a favorable safety profile in randomized trials for moderate-to-severe atopic dermatitis (AD), but real-world evidence is limited. We conducted a multicenter, retrospective...
OBJECTIVES: Baricitinib has shown efficacy and a favorable safety profile in randomized trials for moderate-to-severe atopic dermatitis (AD), but real-world evidence is limited. We conducted a multicenter, retrospective and prospective study aimed at evaluating the long-term effectiveness and safety profile of baricitinib in the treatment of adult patients affected from AD, with the additional goal of identifying potential predictors of treatment response. METHODS: We included adult AD patients treated with baricitinib between January 2023 and November 2024 at five Italian tertiary centers. Disease severity and patient-reported outcomes, including the Eczema Area and Severity Index (EASI), Body Surface Area (BSA), Itch Numeric Rating Scale (Itch-NRS), Sleep Numeric Rating Scale (Sleep-NRS), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), and Minimal Disease Activity (MDA, defined as EASI ≤3 and Itch-NRS ≤1), were assessed at baseline and weeks 4, 16, 32, and 52. RESULTS: The 52 patients enrolled showed significant and sustained improvements in physician- (BSA, EASI) and patient-reported outcomes (Itch-NRS, Sleep-NRS, DLQI, POEM). At week 16, atopic comorbidities increased the odds of achieving MDA (OR: 10.9; = 0.033), whereas head and neck involvement reduced the likelihood of response (OR: 0.07 = 0.028). Thirty-two mild to moderate adverse events occurred in 28 patients, none requiring treatment discontinuation. CONCLUSION: In this real-world study, baricitinib provided substantial long-term effectiveness with a favorable safety profile in moderate-to-severe AD, and atopic comorbidities emerged as a predictor of optimal clinical response at week 16.
A CollaboraTive Initiative of worldwide Vitiligo Experts and patients to define vitiligo activity (ACTIVE): study protocol.
Delbaere L, Vanden Broucke L, Wolkerstorfer A … +6 more , Prinsen CAC, Passeron T, Ezzedine K, Seneschal J, Speeckaert R, van Geel N
J Dermatolog Treat · 2025 Dec · PMID 41164965 · Publisher ↗
OBJECTIVES: The ollaboraive nitiative of worldwide itiligo xperts and patients to define vitiligo activity (ACTIVE) project aims to develop standardized definitions and criteria for assessing disease activity in vitiligo...
OBJECTIVES: The ollaboraive nitiative of worldwide itiligo xperts and patients to define vitiligo activity (ACTIVE) project aims to develop standardized definitions and criteria for assessing disease activity in vitiligo using a consensus-based, multi-stakeholder approach. METHODS: The project is divided into three main topics. Topic 1 focuses on standardizing the definition and terminology of clinical signs of disease activity, using literature reviews, iterative e-Delphi surveys, and a consensus meeting. Topic 2 aims to classify disease activity into distinct activity categories by differentiating between slowly and highly progressive vitiligo. This will involve a literature search, a patient focus group, an e-Delphi survey, and a final consensus meeting. Topic 3 addresses remaining challenges in defining and assessing disease activity in vitiligo. This will include, for instance, the definitions of stability versus activity. In addition, unresolved issues and feedback identified by working groups 1 and 2 will further contribute to working group 3 with the aim of reaching a global consensus on all other key concepts of disease activity in vitiligo. RESULTS/CONCLUSION: By engaging international vitiligo experts and patients/patient representatives throughout the process, the ACTIVE study is designed to enhance consistency in disease activity definitions across multiple centers. This will improve the comparability of outcomes, facilitate management, and support clinical trials evaluating new treatments with more reliable inclusion.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe